Primary Record
Taselisib
- In stock
- 6,423 g
- Purity
- 98.6 %
- CAS
- 1282512-48-4
Compound Identifiers & Properties
- CAS
- 1282512-48-4
- PubChem CID
- 51001932
- SMILES
- CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
- Canonical SMILES
- Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1
Names & Synonyms
- Taselisib
- GDC-0032
- 1282512-48-4
- taselisibum
- Taselisib [INN]
- Taselisib (GDC0032)
- Taselisib [USAN:INN]
- TaselisibGDC-0032
- GDC 0032
- GDC0032
- TaselisibGDC-0032?
- Taselisib (USAN/INN)
- TASELISIB [USAN]
- RefChem:891186
- D0UP1Z
- UNII-L08J2O299M
- TASELISIB [WHO-DD]
- Taselisib (GDC 0032)
- Taselisib (GDC-0032)
- L08J2O299M
- MFCD26142641
- CHEMBL2387080
- DTXSID00155842
- RG-7604
- RG7604
- C24H28N8O2
- GTPL7794
- orb1306789
- SCHEMBL1485247
- DTXCID9078333
- SCHEMBL29356334
- 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
- SYN1202
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N
- GLXC-90374
- HMS3674G19
- AMY39941
- BCP09253
- EX-A1581
- RG 7604
- BDBM50434806
- NSC777425
- NSC800985
- s7103
- ZINC68267049
- AKOS026750303
- ACN-036695
- CCG-269338
- CS-1817
- DB12108
- EBC-216027
- GDC-0032, Taselisib; RG-7604
- NSC-777425
- NSC-800985
- SB16576
- KS-00001D74
- NCGC00387039-02
- AC-32794
- AK343038
- AS-10662
- BG166285
- HY-13898
- QC-11626
- RO5537381
- S7103,GDC0032,RG7604
- B1047
- NS00072930
- J3.190.696B
- A12831
- D11774
- Z-3154
- A855667
- BRD-K44844162-001-01-6
- Q27088940
- 1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha,alpha-dimethyl-
- 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide
- 2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide
- 2-(4-(2-(1-ISOPROPYL-3-METHYL-1H-1,2,4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO(F)IMIDAZO(1,2-D)(1,4)OXAZEPIN-9-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPANAMIDE
- GDC-0032, 98%, a potent beta-sparing small molecule inhibitor of PI3K - 25MG 25mg
- 1282513-03-4
- 1395408-87-3
- 1H-PYRAZOLE-1-ACETAMIDE, 4-(5,6-DIHYDRO-2-(3-METHYL-1-(1-METHYLETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO(1,2-D)(1,4)BENZOXAZEPIN-9-YL)-.ALPHA.,.ALPHA.-DIMETHYL-
- 1H-PYRAZOLE-1-ACETAMIDE, 4-(5,6-DIHYDRO-2-(3-METHYL-1-(1-METHYLETHYL)-1H-1,2,4-TRIAZOL-5-YL)IMIDAZO(1,2-D)(1,4)BENZOXAZEPIN-9-YL)-ALPHA,ALPHA-DIMETHYL-
- 1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-|A,|A-dimethyl-
- 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide(GDC-0032)
- 2-[4-[2-(2-isopropyl-5-methyl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]-2-methyl-propanamide
- 2-methyl-2-(4-(4-(3-methyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl)-9-oxa-3,6-diazatricyclo(8.4.0.0^(2,6))tetradeca-1(14),2,4,10,12-pentaen-12-yl)-1H-pyrazol-1-yl)propanamide
- 2-methyl-2-(4-{4-[3-methyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradeca-1(14),2,4,10,12-pentaen-12-yl}-1H-pyrazol-1-yl)propanamide
- 4-(1-Isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-12-[1-(1,1-dimethyl-2-amino-2-oxoethyl)-1H-pyrazole-4-yl]-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradecane-1(14),2,4,10,12-pentaene
- 4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-|A,|A-dimethyl-1H-pyrazole-1-acetamide